Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are โฌ39.69 Billion. In 2023 the company made an earning of โฌ14.84 Billion, an increase over its 2022 earnings that were of โฌ9.41 Billion. The earnings displayed on this page is the company's Pretax Income.